Last edition
News about "Biocon Pharma"
Biocon Pharma Receives US FDA Nod for Tofacitinib Extended-Release Tablets
Biocon Pharma has received approval from the US Food and Drug Administration (US FDA) for its ANDA for tofacitinib extended-release tablets, securing final approval for the 11 mg strength and tentative approval for the 22 mg strength.
Biocon Pharma | 19/11/2025 | By Dineshwori | 100
Biocon and Carnegie Secure Tentative FDA Approval for Rifaximin Tablets
Biocon Pharma, a wholly owned subsidiary of Biocon Ltd., in partnership with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.
Biocon Pharma | 07/10/2025 | By Dineshwori | 199
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy